Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma

This translational study will examine the immune effector responses of patients who received a two-drug combination for first line therapy by examining tumor and peripheral blood of participants with unresectable locally advanced or metastatic melanoma.

NCT Number	NCT07223411
Lead Sponsor	John Kirkwood Collaborators: Regeneron Pharmaceuticals
Conditions	Locally Advanced Melanoma
Enrollment	20 participants
Start Date	2025-11-19
Primary Completion	2028-11-01 (estimated)
Study Completion	2031-11-01 (estimated)
Updated on ClinicalTrials.gov	2025-11-26